Q1 2022 Charles River Laboratories International Inc Earnings Call
Okay.
Ladies and gentlemen, thank you for standing by and welcome to the Charles River Laboratories first quarter earnings Conference call. At this time all participants are in a listen only mode. Later, we'll conduct a question and answer session. If you have a question press one and then zero. Please press one and then zero just wants to.
Placed into the Q&A queue.
If you should require assistance on today's call Press Star and then zero as a reminder, this conference is being recorded I would now like to turn the conference over to your host Todd Spencer Vice President of Investor Relations. Please go ahead.
Thank you Lisa good morning, and welcome to Charles River Laboratories, first quarter 2022 earnings Conference call and webcast. This morning, I'm joined by Jim Foster Chairman, President and Chief Executive Officer, David Smith, Executive Vice President and Chief Financial Officer, and Flavia, Pease Executive Vice President and incoming Chief Financial Officer.
They will comment on our results for the first quarter of 2022. Following the presentation. They will respond to questions. There is a slide presentation associated with today's remarks, which is posted on the Investor Relations section of our website at IR Dot <unk> Dot com.
Webcast replay of this call will be available beginning approximately two hours after the call today and can be accessed on our investor Relations website.
The website the replay will be available through next quarters conference call.
I'd like to remind you of our safe Harbor, all remarks that we make about future expectations plans and prospects for the company constitute forward looking statements under the private Securities Litigation Reform Act of 1095 actual results may differ materially from those indicated during this call. We will primarily discuss non-GAAP financial measures, which we believe.
Help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results from operations prepared in accordance with GAAP in accordance with regulation G. You can find the comparable GAAP measures and reconciliations on the Investor Relations section of our website I will now.
Turn the call over to Jim Foster.
Thank you Todd good morning.
I'm pleased to report solid financial results for the first quarter that we are precisely in line with our expectations.
Organic revenue growth was slightly below the 10% level operating margin improved by 70 basis points year over year and earnings per share growth was in the high single digits.
The revenue growth rate is expected to increase from the first quarter level positioning us well to achieve our robust outlook for the year.
There are several factors that we believe support our outlook, including the continued strength of the biopharmaceutical market environment first we continue to benefit from strong sustained business trends, particularly in our largest business safety assessment, which represents approximately half of our total revenue.
We are booking work well into 2023 and have over $1 billion of backlog already for next year we.
We continue to get price and anticipate continued share gains.
Our scale scientific expertise and geographic reach continues to resonate with our clients. We have added a significant number of staff in the second half of last year and continued hiring in the first quarter.
Coupled with our growing backlog, we are poised to meet the escalating demand, which will result in a DSA organic revenue growth rate approaching 20% in the second half of this year.
And the other factor that supports our 2022 outlook is a well funded client base, both large and small based on daily conversations with our clients and our key performance indicators clients are continuing to spend at the rate that we anticipated.
And move the non clinical development programs forward.
Given our early stage focus we are a canary in the coal mine should funding become a concern. This is not surprising as we believe biotech clients are resilient and continue to have an average of about three years of cash on hand based on both our internal assessment and our clients and industry research.
Industry sources.
The biotech industry is more critical to biomedical innovation than ever.
<unk> generally unaffected by the recent headlines related to public biotech financing.
Beyond the public markets, we believe that broader balanced sources of funding will enable many biotechs to continue to access capital from the private sector.
Venture capital firms continue to raise new larger funds and invest heavily in the startups, providing a sustained source of funding for the biotech industry. We.
We believe that pharma M&A and <unk> investments are also utilize to help ensure that promising molecules for unmet medical needs are funded and move forward to provide some color on our biotech client base roughly one quarter of our clients can be defined as pre commercial segmenting that further.
There is a subset of public biotech clients with less than two years of cash on hand, we estimate that these clients make up only about 10% of the current DSA backlog.
We have taken action in recent years to add staff capacity scientific capabilities and secure resources to accommodate client demand and provide them with exceptional service. These.
These assets have intensified recently in order to support the robust growth we are experiencing and continue to forecast. We are confident that we are taking the necessary steps to effectively manage the business in today's market environment and deliver on our commitments to clients, we believe that our.
Our ability to support our clients with flexible efficient outsourcing solutions tailored to their needs and available when they need them has continued to distinguish us from the competition.
I will now provide highlights of our first quarter performance.
We reported revenue of $913 9 million in the first quarter of 'twenty two at 10, 8% increase over last year.
<unk> revenue growth of nine 4% was driven by a solid performance from all three business segments.
Was in line with the outlook that we provided in February biotech clients continue to be the primary driver of revenue growth in the first quarter. The operating margin was 21, 4% an increase of 70 basis points year over year.
Improvement was driven by the RMS segment, as well as lower unallocated corporate costs.
<unk> per share were $2 75 in the first quarter, an increase of eight 7% from the first quarter last year strong mid teens operating income growth was partially offset by a higher tax rate and interest expense compared to the prior year.
Based on our first quarter performance and an expectation that the robust business trends will continue throughout the year, we are maintaining our organic revenue growth guidance of 12, 5% to 14, 5%.
Our non-GAAP earnings per share guidance of $11 50.
To $11 75.
2022.
Our guidance has incorporated two unfavorable changes in below the line items since the beginning of the year the expectation for a slightly higher tax rate. This year due to the impact of a lower stock price on stock based compensation and higher interest expense as a result of the federal Reserve's recent monetary policy changes.
David will discuss both of these items in more detail shortly.
I'd like to provide you with the details on our first quarter segment performance beginning with the DSA segment revenue was $554 $3 million in the first quarter and 95%.
Year over year increase on an organic basis as expected the DSA organic growth rate improved by nearly 300 basis points from the fourth quarter level driven by the safety assessment business, we expect that growth to improve to the low double digits in the second quarter. It approached 20% in the second half.
As the quarterly gating for the year continues to track to our initial plan.
The safety assessment business continued to benefit from strong business trends as higher pricing and increased demand drove first quarter revenue growth. We are pleased with the sequential improvement in safety assessment growth rate and I expect continued acceleration during the year. This is supported by booking in proposal activity, which remain robust.
Just DSA.
DSA backlog was $2 8 billion at the end of the first quarter, an increase of more than 75% in the first quarter of last year and over 15% since year end proposal dollar volume in the safety assessment business increased by 35% year over year.
We also have an exceptionally high proportion of safety assessment revenues booked into backlog already for this year.
But do you have sufficient capacity to start certain studies during the year. These trends reinforce our DSA organic revenue growth expectation for the year and affords us the visibility into the strongest future demand that we have ever seen.
<unk> is well utilized both in terms of people and infrastructure and we are continuing to add the necessary staff asked space to accommodate these robust demand trends.
As I mentioned earlier, we hired a significant number of safety assessment staff in the second half of last year and hiring continued into the first quarter with the staff now in place. We expect recent hires will help us meet our accelerating DSA growth outlook over the course of the year.
Coupled with benefits from higher pricing continuing to work through the backlog, we are very confident and the anticipated DSA growth acceleration and our ability to achieve our mid teens DSA organic revenue growth outlook for the year, including approaching 20% growth in the second half.
Our clients are also accepting longer lead tax required to start some of the studies, which is necessitating let's say book projects further in advance to ensure that they do not delay the drug development. Many of our explore ensing exploring new created relationships with us to secure space.
These discussions recently led to a large biopharmaceutical clients to enter into a multiyear agreement with us to reserve safety assessment capacity and a take or pay arrangement. We anticipate that other clients will follow suit and believe that these developments demonstrate the sustained strength of the demand environment in our market.
<unk> position as a leading non clinical contract research organization.
Revenue for the discovery business increase in the first quarter, but growth rate was below its recent low double digit trend. This was largely the result of a difficult comparison to the strong first quarter of last year, which included milestone payments and some COVID-19 related work.
Our integrated discovery portfolio continues to resonate with clients and it is imperative that we enable them to have access to cutting edge scientific capabilities and expertise in major therapeutic areas as well as biologics. So that we can be the scientific partners. They work with to advance the research programs too.
The IND filing and beyond.
Our technology partnership strategy has been very successful means to do this it has enabled us to continue to add new capabilities across many of our businesses with limited risk.
We believe our clients' willingness to outsource more of their discovery programs will be predicated on our ability to continue to add innovative capabilities to meet.
Critical research needs.
The DSA operating margin decreased by 90 basis points to 22, 9% in the first quarter due primarily to higher staffing costs.
We view this largely as a timing issue given a significant number of new hires and wage environment over the past six to 12 months for the year. We continue to expect the DSA segment will be the primary driver of modest operating margin improvement for the company as leverage from the accelerated DSA growth rate.
Thats higher compensation cost.
RMS revenue was $176 5 million, an increase of eight 7% on an organic basis over the first quarter of 'twenty, one and in line with our high single digit outlook for the year.
Organic revenue growth was driven by broad based demand and meaningful price increases in the research model business, particularly in North America, which performed very well China also continued to perform well, but the growth rate was impacted by the comparison to the exceptionally strong start last year. We also experienced a very small.
RMS revenue impact related to China's COVID-19 restrictions this year and are closely monitoring the situation at this time, we don't expect it will be kind of a meaningful headwind.
Research model services was also a significant contributor to the segment's growth led by the insourcing solutions business or EIS.
Our credo or Charles River accelerator and development labs initiatives, which.
Which is part of our <unk> business has further accelerated the growth potential for the RMS segment as both small and large biopharmaceutical clients are increasingly seeking to rep turnkey research capacity in key bio hubs.
To build upon a cradle strategy and capitalize on the significant growth opportunity, we acquired explorer bio labs last month, San Diego base Explorer has a similar focus as cradle.
Currently operating more than 15, preclinical vivarium facilities with greater presence on the west coast, while the demand for turnkey laboratory capacity makes this an attractive transaction on its own.
The enhanced value proposition is that clients utilizing cradle or explorer, we will be able to easily access additional services across a comprehensive discovery and clinical development portfolio, providing us with a new and unique pathway to connect with clients at earliest stages with.
With expansions currently underway in the United States and internationally the combined cradle and explore operation is expected to include at least 25 vivarium facilities by the end of 'twenty, two providing over 300000 square feet of turnkey retro capacity and keep Iowa.
Floor bio labs will effectively double the revenue and footprint of our cradle operation driving strong double digit revenue growth that will solidify the RMS segment's position as a sustained growth engine for the company.
In the first quarter, the RMS operating margin increased to 120 basis points to 29, 9% driven primarily by operating leverage from robust sales of research model.
RMS operating margin expansion will be limited for the remainder of the year due to the explorer Biolab acquisition, Florida has healthy margins for service business.
But the operating margin is below that of the RMS segment, creating a headwind to the segment margin. This year explorer is opening a number of new sites. This year. So we expect the business to leverage these investments and be better positioned to enhance its operating efficiency thereafter.
Revenue for the manufacturing segment was $193 1 million or.
10, 1% increase on an organic basis over the first quarter of last year Biologics testing services was the primary driver of the increase.
With continued robust double digit revenue growth.
Microbial solutions growth rate was below the 10% level.
<unk> on the manufacturing segment's growth rate being below mid teens full year target in the first quarter. This was timing related and will not affect the outlook for the year as we still expect microbial revenue growth in the 10% range.
Demand for our biologics testing services associated with cell and gene therapies and other complex biologics continues to be robust.
And we are confident that cell and gene therapies will continue to be significant growth drivers.
For our business, even as Covid related vaccine.
Testing revenue settles into a steady run rate.
There is a significant market opportunity for our biologics testing business, which provides services that support the safe manufacture of biologics.
Including process development and quality control.
We believe client interest in our consolidated biologic solutions offering.
Which provides both biologics testing and the cell and gene therapy, CMO services will only increase as the synergies to produce complex biologics and conductor required analytical testing with one scientific partner more.
More broadly adopted by clients.
Utilizing our biologic solutions offering will be a strategic advantage for clients, who are looking to reduce bottlenecks and increase efficiency of their drug development and commercialization efforts.
As CMO business also had a good quarter and we continue to make excellent progress on our integration efforts as gene modified cell therapy production business has gained traction and generate strong growth in the quarter as it continues to be one of the leaders in this emerging space.
Benefited from commercial readiness milestones in the quarter, which are relatively common in the <unk> sector and demonstrates our clients are continuing to advance their programs into later stages of development and trust us to take the critical.
Next steps with that we also continue to position our gene therapy product offering plasma DNA viral vectors to be opportunistic in a marketplace that is greatly in need of our supply.
The manufacturing segment's operating margin declined 240 basis points to 33, 1% in the first quarter of 'twenty two as a result of the inclusion of the cognate advice businesses, which have margins below the overall segment, but expect it to improve as we drive efficiency and leverage the significant growth potential.
For this business.
We are operating in a robust business environment. It gives us excellent growth potential we have the best visibility that we have ever had with an average 12 to 18 months of backlog in our largest business.
We have the capacity and the people in place to deliver on the accelerated demand throughout the year and we are benefiting from escalating pricing. It is opportune at the market dynamics will remain robust at a time when we believe we have built a premier nonpolitical contract research and manufacturing organization.
Before I conclude I'd like to provide an update on our CFO trends pension plan as we announced last month.
<unk> has been named our next Chief Financial Officer, replacing David Smith, who previously announced his plans to retire I'd like to thank David for his dedicated service to Charles River at a remarkable career.
David has been instrumental in Charles River as growth at success since he joined the company to the agenda and bio focus acquisition in 2014.
Subsequently when he was promoted to chief financial Officer in 2015.
During his tenure as CFO Charles river's revenue has increased 17% annually and free cash flow by 14% annually and David has played a critical role in his accomplishments by providing a strategic financial counsel and direction to our global organization, David will remain with us through year end.
By transitioning into a role as senior financial adviser shortly after earnings.
Pleased to announce a slot <unk> will assume the role as CFO at that time Flavio is the highly regarded financial leader with more than 20 years of financial leadership experience at Johnson <unk> Johnson.
Deep fire biopharmaceutical industry knowledge and experience managing with finance organizations of large growing businesses will greatly benefit Charles River I look forward to partnering with slightly as we work to advance the companys growth strategy and mission.
In conclusion, I would like to thank our employees for their exceptional work and commitment and our clients and shareholders for their support now Flavio will provide a brief introduction before David gives you additional details on our first quarter financial performance in 'twenty two guidance.
Thank you Jim I'm excited to join the Charles River family and become Chief Financial Officer, Charles River presents a compelling opportunity to join the life Sciences industry leader work with a deep and talented finance team and collaborate with Experian senior leaders.
I intend to leverage my experience as a trusted business partner to help the company achieve its financial goals supported significant growth potential and create value for shareholders. I look forward to meeting many of you in the investment community in the coming weeks and months.
I'd also like to thank David for his support and guidance over the past few weeks and I will continue to work closely with him to ensure a smooth and seamless transition now I will turn the call over to David.
Thank you Jim and good morning.
Before I begin may I remind you that I'll be speaking primarily to non-GAAP .
Each exclude amortization of acquisition related charges.
Costs related primarily to our global efficiency initiatives.
Capital.
<unk> investment performance and serve more clients many.
Many of my comments will also refer to organic revenue growth, which excludes the impact of acquisitions divestitures and foreign.
Currency translation and.
2022.
We are pleased with our third quarter performance, which included revenue and earnings per share growth in line with the outlook we provided in February .
Organic revenue growth of nine point.
And operating margin expansion of 70 basis points, partially offset by a higher than expected tax rate, resulting in an earnings per share increase of eight 7% to $2 75.
Sam.
As Jim mentioned, we have reaffirmed organic revenue growth and non-GAAP earnings per share guidance.
Our earnings per share guidance of $11 50 to $11.
Okay.
Hi, Anthony.
Right and interest expense.
Our initial outlook.
I will discuss both of these items in more detail shortly.
Our organic revenue outlook for the full year unchanged.
Beauty group.
Great.
With the addition of explorer Biolab, we've increased reported revenue growth guidance to a range of 13 to 15, 5%.
This includes the launch of a one point headwind from foreign exchange due to the strengthening of the U S farmer.
Given the robust topline performance, we remain well positioned to moderately expand the operating margin in 2022.
As I mentioned on tax rates and interest expense.
The increase at the beginning of the year, we expect a slightly higher tax rate in 2022.
The low spot trends during the first quarter resulted in a loan.
Associated with it.
This led to a fourth quarter tax rate of 16, 8%, a 250 basis point increase year over year and above.
In the mid teens.
And outlook remained within our initial low 20% range for the year.
Has moved slightly higher due to the stock price movement since February .
We now expect.
Interest expense of $98 million to $102 million in 2020 to approximately $50 million higher than that.
Thank you.
The primary drivers of the increase nearly evenly split between higher interest rate assumption associated with that.
The outlook provided in March and higher debt balances due to the explorer acquisition in April .
Which will not have a meaningful impact on non-GAAP earnings per share since the transaction is expected to be earnings neutral this year.
First quarter total adjusted.
Adjusted net interest expense was $24 million, which was flat sequentially compared to the fourth quarter.
At the end of the first quarter, we had an outstanding debt balance of $2 7 billion equates.
Equating to a gross leverage ratio of two five times and a net leverage ratio of two okay.
<unk> refinance or acquisition.
Growth in credit facility and our leverage remains below three times pro forma for the transaction.
For the remainder of 2022, we will continue to evaluate M&A opportunities.
Any additional acquisition.
These priorities will be focused on debt repayment.
I second.
Organic revenue growth I think the 2022 remains unchanged.
Organic revenue growth guidance remains in the high single digits.
We reported revenue growth.
<unk> is being increased to a high single digit range to include exploring a revenue contribution.
We continue to expect the DSA segment to deliver mid teens organic revenue growth driven by strong contributions from both the discovery and safety assessment businesses.
The manufacturing segment to achieve mid teens organic growth and the microbial solutions growth rate improved from the fourth quarter level and appropriately and <unk> acquisition.
Okay great.
Lola unallocated Coca Cola, Turkey, and 5% of revenue contributed to the fourth quarter operating margin improvement.
This is compared to six 2% of revenue last year.
The decrease driven by several factors, including favorable fringe related costs and quarterly fluctuations, indicating a corporate cost.
Despite the favorability in the first quarter, we continue to expect.
Corporate expenses to be in the mid 5% range as it essentially.
Yes.
Free cash flow was $22 2 million goes in the first quarter compared to $142 $2 million last year.
The decrease of $120 million over the prior year was primarily due to planned increase in capital expenditures associated with project to support future growth and higher performance based bonus payments related to the strong 2021 results.
Capital expenditures were $80.
Third quarter compared to $28 million last year.
For the year, our free cash flow and capital guidance remains unchanged at approximately 450 $360 million respectively.
Previously discussed.
It is expected to total approximately 9% Turkey revenue in 2022.
A summary.
<unk> financial guidance for the full year can be found on slide 39.
The second quarter.
This reflects the continuation of the strong business trends and.
So the revenue growth rate to continue to accelerate.
We expect reported and organic revenue growth rate will be in low double digits.
The DSA environment organic growth rates are expected to improve sequentially from the first quarter level, while our manufacturing segment will be slightly lower due to the strong components into the nearly 27% growth last year.
Earnings per share are expected to increase in the mid to high single digits year over year in the second quarter.
In closing we are very pleased with our first quarter financial performance and a comprehensive long term growth prospects for the remainder of the year.
The strong DSA business development activity that Jim highlighted our ODP family supports our full year financial guidance, including DSA organic revenue growth approaching 20% in the second half of the year.
Before concluding I would like to say a few final words Im pleased to welcome <unk> to the chunk of the team.
In the past few weeks, we began the transition of my responsibilities and as such this will be my final earnings call as Chief Financial Officer.
We're not officially retiring until after year end.
We will move into a new role shortly.
It's cool to insurance new transition.
It has truly been a privilege to serve as chair.
And I would like to thank Jim Board and all of my colleagues for their support and collaboration during my time at challenges and for the successes that we will share it together.
We believe our company.
Well positioned for continued success because of the sustained robust demand environment, our industry, leading portfolio and the highly experienced leadership team.
I would also like to thank each of you a chunk of the shareholders of normal for the collaborative relationships that we've forged over the years and for your support it's been a pleasure working with you. Thank you.
That concludes our comments operator, we will now take questions.
Ladies and gentlemen, if you wish to ask a question. Please press one and then zero on your telephone keypad.
You may withdraw your question at any time by repeating the one zero command.
If you are using a speaker phone please pick up the handset before pressing the numbers and please limit yourself to one question. Once again, if you have a question. Please press one and then zero at this time.
Our first question will come from the line of Eric <unk> with Baird. Please go ahead.
Yeah.
My question two questions on <unk>.
TSA segment first one.
DSA growth expected to approach, 20% in the second half I'm curious if there is any additional.
Color available on the split between <unk> and <unk> I E would both be at a similar rate or would the ramp continue through the year.
Finishing out at or above that range in the fourth quarter and then my second question I believe I heard you say there was a take or pay deal in DSA done this quarter.
Juggling a few calls today, so I missed that section but.
Im curious if you can provide any more detail on that.
<unk>.
What you think the.
The client appetite for further take or pay deals might be at this time, thanks very much.
Sure. So we do anticipate the ramp will continue.
Through the back half of the year.
Each quarter will be progressive should be progressively stronger.
We will add.
Well the back half of the year of 20% and that's a combination of significant price.
Share gain.
Overall volume and mix, great capacity utilization utilization of staff, which has been.
Higher debt being trained and sort of not contributing to the California. The bottomline.
Q1.
And just the strength of our.
Competitive.
<unk> from a scale point of view geographic proximity point of view.
The constituent.
So we've.
We've never had backlog like as it continues to elongate.
That's $1 billion of backlog already for next year.
The volumes are up substantially over the prior year over the last quarter. So we're quite confident.
And our numbers and our progression take a pacing Eric is really interesting.
To your second.
Second at least to ourselves.
We were surprised we werent hearing more of this capacity is kind of appropriately tie.
Clients are really busy clients, well finance lots of new modalities people are booking pretty far out.
The booking pretty far out is the combination of lots of work and making sure. They get a slot and driver I've often said if I was running a drug company or the head of R&D.
Certainly we try to lock up some space and flexibility.
Could slot things and perhaps slide priority things when perhaps earlier that we were giving them.
Giving that slot so.
We signed the first one.
It's nothing special about the client, except it's a big one and it's about the year.
We feel pretty strongly that others will follow.
Too much of an appropriate tool for them to use.
The demand continues to increase.
A safety valve, which I think takes a lot of the pressure off of that.
We spent a lot of time with our clients over the last six to 12 months about tell us what your real priorities are John tell US every drug is important to start a study next month or going to have the same revenue contribution because of course, that's not true help us prioritize and well a help slot those in earlier, Andy if you want to really be.
Sure Gautam suspenders and lock up some space on a take or pay basis. So not surprised pleased to see it I think thats going to make us kind of sketch.
Scheduling more rationale while comfortable for everybody and we cant project because it hasn't happened yet, but we would be surprised if we don't see additional large companies do similar things by the end of the year.
Jim Thanks, very much for the details.
Jump back in queue, if I have anything else congrats on the outlook.
Thanks Aaron.
Thank you. Our next question comes from the line of Jacob Johnson with Stephens. Please go ahead.
Hey, good morning, Thanks for taking the question Jim I wanted to follow up on something you alluded to in your comments.
In terms of the cell and gene therapy.
Okay.
Clients, you have in biologics and kind of your ability to.
We want to call it pull through or cross sell them.
<unk> can you just talking about the initial reception there and what's your experience has been.
Yes.
It was.
I'd say the major strategic rationale for us to pivot back into the CMO space.
Having exited several years ago.
We find ourselves with is escalating hi.
High growth.
Improving margin biologics business on a worldwide basis. So we're testing the drug before it goes into the clinic.
Testing a drug if.
If it's improved asset goes in the clinic, perhaps indefinitely.
And we began to have request from clients to why can't you manufacture the drug. So there is a correlation so if we if someone else manufacturers that we can still tested.
It's for us, but I think there is a lack of elegance to that from the clients I think it's less.
Less efficient for that.
Slows things down so.
And so we have competitors, who do both sorry, who do I've ever going to vote.
We think this is a strategic benefit for US also the same the connection to safety discovery is also quite significant so.
It's a little bit early to comment on the success, except to say that we have a sales force that talks about all of it we have clients that definitely are resonating to it both ways. So former.
Biologics clients, who are now beginning to talk to us about or use us for.
I see the amount of manufacturing or buying.
Gene therapy products or vice versa. So.
We are quite confident that that's the ultimate value proposition that we've invested in here that's sort of the way we get one plus one equals three.
Got it and then just maybe following up on that.
On <unk> can you just talk about the latest trends in cell supply kind of the COVID-19 headwinds there abated or are you seeing a rebound in those businesses.
So <unk> has new management.
Has new capacity.
And has much more sophisticated ways to access.
And hopefully retain donors.
So the slope of that business is positive as we move through the back of the year.
Yes.
Got it thanks for taking the questions.
Thank you we do have a question from Elizabeth Anderson. Please go ahead.
Hi, guys. Thanks, so much for the question Youre welcome.
It's nice to speak with you.
I was wondering if you could talk to me a little bit more about sort of the opex spend in the quarter that came in a little bit under what we were.
Respecting, especially given the inflationary environment just any additional puts and takes you can sort of talk about on that so we can sort of think about the run rate for the rest of it.
Yes.
Sure.
No question.
So speaking of real quickly.
<unk> expenses in the current kind of inflationary environment, yes.
Yes.
We.
Yes.
I think anybody has a crystal ball, but we feel that we accommodated well for inflationary pressures when we put our operating plan together.
And it's embedded in our guidance when I say that I am obviously talking about.
Supply chain costs.
Principally about numbers of people and.
Salary levels hourly rates whatever.
Compensation levels than what we anticipate.
That we have already done and they have to do Additionally.
There's no question that in the first quarter tried to allude to this my answer to the last question. We had a fair number of people that were hired for instance into the safety assessment business. So more people.
Higher salary levels.
Very much tied up in training and not really contributing.
To either revenue or profitability, so youll see that sort of ameliorate through the back half of the year you.
You will see pricing for a lot of states that we booked later in the year come through so what we said.
State. This again carefully is that.
The modest anticipated operating margin accretion that we believe that we will get for this year will be principally as a result.
The safety assessment business.
Those costs are embedded in that analysis.
Got it that's very helpful.
Thank you.
Thank you we have a question from Elizabeth range with William Blair. Please go ahead.
Hi.
Great.
Thanks for the question.
I was hoping you give me an update on your plasmid DNA business.
This is an area of investment for Charles River, and how does it stay in check.
Offering for cell therapy innovators in that strategy.
Yeah. So.
Working hard to enhance the management of all of these businesses that we bought to sort of refine the strategy for both our plasmid DNA and viral vector businesses.
What you're going to be sort of geographically based.
Sort of moving away from some of the work that one of those businesses was doing that was very much COVID-19 related.
Before we bought it right after we bought it and now that we have we.
We have capacity available.
For a plasma DNA so.
We.
We're positioned really well for this gene therapy product offering.
And we're just going to allow us to be opportunistic in the marketplace, where there appears to be insufficient supply to meet the demand. So we feel really good about.
Our ability to.
Provide those essential products to our clients in that space.
And does that answer your question.
Yes, great. Thank you. Thank you. Our next question comes from Dave Windley with Jefferies. Please go ahead.
Hi, Good morning, Thanks for taking my questions David Congrats on your great career and best wishes in retirement I wish I was following you.
The question I have I wanted to focus Jim I appreciated your your data on your client mix.
Vince Your funding has actually I think held up even a little bit better than the public markets I wondered if in addition, you had any sense of.
What the mix is of your probably your pre commercial that are venture versus public any sense of that.
Okay.
I don't think.
Size of the ship.
I mean, we've said less than 10%.
For the small pre revenue businesses I think I think a lot of those are public.
Bob.
I think as you said in your question.
We have a lot of formal and informal relationships with pretty much all of the major health care venture capital firms.
Thank you now.
Yes.
There are raising funds much more quickly than they used to so five to seven year raises going out two to three year raises at.
It seems like those companies are two things, which are good for us extremely well financed and have no desire ability capability or interest.
In developing any of their own internal capacity to frankly do any of the things that we do so there.
In some ways the best clients they have they're always in a race.
To get to market at least get to proof of concept.
Less price sensitive.
They are well financed.
100% outsourced as at least at least yes.
Almost all of them or so.
So.
We feel that just to give you a broader answer to that.
Maybe the product question, there was kind of a follow up.
We feel that the clients have three years of cash generally we feel that those that may have less than two years of cash.
I think three things I think that.
Pharmaceutical industry will bank a lot of those companies and allow those technologies Android the Vcs I think any new.
Potential drug.
To deal with unmet medical needs that really is promising I just don't think that the pharmaceutical industry is going to let that languish and not support it. So I think it's highly unlikely that these companies somehow flourish.
Somehow get.
And somehow continue to work with US having said all of that based upon the numbers that we just gave you in our prepared remarks, we see lawn gating back.
Backlogs.
We see enhanced pricing, we see increased demand we see.
C.
That grows client to do a deal to take or pay basis. So.
It seems like our client base is strong.
That has full.
No.
Our product portfolio.
Is not concerned about their ability to fund those going forward.
Thank you.
Yes.
That segways into my follow up which was take or pay.
Eric asked this a little bit.
Been a while you've talked about it recently, but it's been a while since we've seen one.
I guess practically speaking I'm wondering you did give us a backlog number this quarter that you don't usually do how is that take or pay.
Contract.
<unk> and backlog if at all.
One is I guess for the for the locking in the space given demand should we assume that you've got kind of spot rate pricing on that take or pay contract or does the client asking for that much get a little bit of discount.
I mean, we're pleased with the pricing of those contracts, it's part of our <unk>.
Client that has.
Higher of our backlog and make sure. It's only a single clients. So we don't we don't want to overstate it.
We wanted to call it out because as I said earlier, we've been anticipating it.
Surprised nobody has done this sooner.
I do think lots of others will follow and I do think this is probably a template natural share with anyone else template for others to have the confidence that for the highest priority.
Studies.
Slide things in earlier.
And also that we get on the same side of the table with them and have a much better strategic dialogue about whats coming out of the types of them when they will need the space.
It gives us great visibility and enhances our plans for how much incremental space. We're building it enhances our plans for how much incremental staff will continue to add just provides a much more rational working relationships with.
We're thrilled with it sounds like we went looking for it but it.
It came up in the conversation.
Our job is to listen carefully to what clients want to provide them with flexible solution.
They don't all watch the same solution, but I do think that some of the larger companies with larger portfolios.
So can afford this.
So the pricing conversation so we actually.
Pharmaceutical companies with billions into tens of thousands of dollars on their balance sheets. They can afford whatever they want so as I've said before I'm, probably the huge specifically Dave.
So many of these drug coming to give an update on internal capacity or reduce it somewhat to a very very smart things for them to do and.
It was pretty much foreseeable and predictable.
Got it thank you.
Thank you. Our next question comes from Casey Woodring with Jpmorgan. Please go ahead.
Hi, guys. Thanks for taking my questions and congratulations David.
I guess, so on DSA, you talked a lot about safety assessment, but can you elaborate on what you saw in discovery you noted that the growth rate was below the recent double digit trend. There. So wondering how much of that is related to the tough comp versus maybe some shifts in customer spend or pipeline rationalization from customers.
Yes, I mean, the discovery business continues to be a strong business that was it.
<unk> more slowly than it has.
Previously the comps were really really tough as we said we had a bunch of COVID-19 related work, which we were happy to have and proud to have but not sustainable and we had some.
Yes, we had some one time events.
Repeatable. So if you if you take that out we feel good about the growth rate.
That business going forward.
Again, that's a service.
A series of services.
So many of our clients need.
Large or small.
Ed.
The service in terms of.
Selling into the safety assessment business, so we like to look at TSA.
At home, which is why we haven't peel it back any further than that but we did give a little bit of color.
This quarter was a bit slower, but we anticipate a strong finish with DSA sequentially, a very strong back half of the year for that whole segment.
Got it and then just wondering how much of the RMS demand you saw in North America is catch up work from canceled or delayed projects from Covid and.
Can you also quantify what the China Lockdown impact was the RMS and <unk>.
Whats implied there in <unk> and for the full year and any other color around China. Thank you.
And so all we can tell you about China, it's kind of a tale of two cities.
Demand is.
Continues to be considerable so we have.
Our growth rate in China that totally outstrips the growth rate in other parts of the world had a nice first quarter tiny impact from the Lockdowns.
We don't anticipate as we said in our prepared remarks.
That it will have a meaningful impact in the second quarter, but it's a little bit impossible to predict.
Our overall feeling is that the RMS segment is so strong.
Unless the impact is greater than we anticipate we'll be able to offset it. So we'll see but right now we feel quite good about it we were particularly pleased with North America I would say that's not a rebound from anything in particular COVID-19 related I would say that.
It's about spending.
Our north.
North American clients, it's about our strength versus the competition, it's about our continued investment.
And in that business and the sophistication of the product line.
A significant pricing.
Some mix and share gains so I can't tell you how delighted we are so.
You have asked us and I'll say it anyway, I mean, I do think that we are living in a renaissance in the RMS business.
Which between China legacy businesses, the service businesses, particularly Ias.
Now enhanced by this explore acquisition that we've done.
We're going to see that business squarely in the high single digits as we move forward.
Hopefully strong operating margins, so we're really thrilled actually with.
Pretty much all the constituent parts and pieces of that business, which.
No.
It's been it's been a while.
While cutting so.
Feel really good about that we will obviously continue to give you updates on the China.
Situations.
So we think we'll be fine.
Thank you.
Thank you. Our next question is from Justin Bowers with J P. Morgan I'm, sorry, Deutsche Bank, sorry about that.
Hi, good morning, everyone.
Just was hoping to.
Get a little more context around the backlog growth in <unk>.
Yesterday, I think you said that you have one 1 billion booked out for 2023.
At this point and.
Versus my model and that's probably 40%.
Of forecasted revenue plus or minus and you really don't have to go too far back.
To where your total backlog for the year with.
$1 billion. So I was just hoping to kind of understand how far out you are willing to go in and also provide some historical context, maybe around like how much you would have booked at this point.
For the following year.
A few years back for example.
I mean, it's unprecedented.
The best before the FCS We had was 67% this is way better.
But it's a totally different industry competitive scenario has totally changed strength with Charles River has totally changed numbers of clients have totally changed.
Biotech as a driver.
<unk> has changed so we have most of the revenue, but we have a backlog this year that will accommodate.
Our guidance.
India.
Safety.
I'm not going to I'm not going to.
Validate your number but you can do the math as to how big you think of safety.
What will grow next year and how much is in backlog, it's much higher than we would see at this point in the year and I would anticipate that we will continue to grow. So hopefully we'll have a similar situation when we get into next year, which is most of it is already.
In backlog.
And that's enhanced by the highest pricing that we've been able to achieve which is appropriate and it's commensurate with the fact that the studies are more complex than they've ever been.
Capacity is.
Appropriately tight.
The clients have more drugs to work on it than ever.
And the competitive the availability of competitive capacity is somewhat limited.
So it's.
It's obviously, a very nice demand curve for us and our job is to try to do all of it to try to build enough space now to the end of 'twenty three 'twenty four to accommodate incremental.
They add to hire people slightly ahead of when they need us to drive our digital portfolio such that we are more efficient and more responsive to our clients.
To kind of price appropriately and rationally.
Two to continue to have more clients have these take or pay.
Relationship with relationships, if thats, what they want.
And also to continue to always save enough space for both short term and longer term size. It just simply absolutely have to start earlier for our clients and we are having as I've said now for several quarters.
We're getting together with all of our clients and just tell us what what your priorities are in our portfolio and we will try to accommodate it so.
A very attractive business model, we're spending all of our time trying to execute against that demand.
But we've never seen in demand like this we're not going to take it for granted we're going to respond really well our execution is going to be as flawless as possible and we're going to have both people and physical capacity in place ahead of when we need it.
I appreciate the color there I'll hop back in queue.
Thank you we have a question from Matt <unk> with Morgan Stanley . Please go ahead.
Hey, guys.
And Dave Congrats on your tenure and best of luck in retirement and Flavia looking forward to working with you.
Jim maybe to start things off did you disclose what organic constant currency growth looked like when adjusting for the Covid impact last year any color you could share in that segment level, perhaps would be helpful.
Yeah, I'd say that Jim.
Yes, we did.
We did call out.
The Covid impact.
By segment when we gave as we went through 2001 and actually at the end of the year, we gave that color. So we had.
980 basis points in RMS, we had 80 basis points in DSA and 210 basis points in manufacturing.
So hopefully that gives you the enemy here looking forward.
Got it that's helpful.
And then Jim as we think about sort of operating margin expansion you did talk about continuing to expect modest expansion year over year can you just walk us through the impact from explorer it sounds that it's going to be a little bit of a headwind on the RMS and then to Dave's point earlier and your commentary around <unk>.
Acting a lot more of these take or pay contracts.
How confident are you that the magnitude of the pricing increases that you foresee working their way through the backlog here can help offset.
Any take or pay sort of headwinds in addition to staffing costs.
Wage inflation.
So we all look at the take or pay deals as headwinds.
Clients are.
Very much.
In need of.
That's sort of a combination of structure for us.
To pay us well for that for those combinations that have that space.
Available so.
I think that would be just part of the portfolio.
Possibly predict how big it will be but.
I think.
Some of the larger clients will want to do the same thing so I don't see that as a headwind im exploring.
So really nice strategic deal is going to double the size of ours.
Rob.
Create a life business, it's going to be a slight headwind to margins in that business. We are having a very high margins and a childhood businesses.
The scale at which they are opening up new facilities and just their overall structure.
Slightly lower margins, which should improve over time, so that's already baked.
That's already baked.
So again, we feel confident that we will deliver this bias improvement that we talked about that's going to come principally from.
Safety I hope it comes.
From other places, but that's not.
What we're guiding to right now, but we do feel that the demand pretty much across the board is quite significant we're in a strong competitive position, we don't really see an external disruptors.
Overall demand.
Got it that's helpful. Jim and one final one on biologics safety testing you spoke about sort of vaccine lot release work, you're settling into steady state for the COVID-19 components heading into the back half of this year and 23.
Can you just.
To help shed some more color around what your assumptions are.
Terms of that steady state demand and if that were to be relatively sharp drop off should we be thinking of a slight moderation here versus that sort of 20% growth target you've spoken about for BSD.
No.
Anticipate.
Demand.
I think we said last year that.
I think we have a 30% growth quarter I think we should take all the COVID-19 work out it still growing at 20%. So really strong growth business. It's all driven by large molecules, there's a multiplicity of different ways large molecules the utilized.
Well in gene therapy is definitely a big driver of our growth. So it's geographic scale. So we're going to do some vaccine for Covid and Covid.
Part of the portfolio, but we won't be whipsawed by any fundamental change in COVID-19 vaccine revenue or test.
Very helpful. Thank you.
Thank you we have no further questions in queue I will turn the conference back to Todd Spencer for any closing remarks.
Great. Thank you for joining the conference call. This morning, we look forward to seeing you at upcoming Investor conferences. This concludes the call.
Thank you that does conclude our conference for today. Thank you for your participation and for using AT&T Executive teleconference. You may now disconnect.